AstraZeneca’s Eplontersen meets endpoints in critical phase 3 trial
Eplontersen significantly improved patient-reported quality of life following successful research
Read More
Tag: eplontersen
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
